The CDMO will add mRNA manufacturing capabilities to its Songdo plant by the first half of 2022.   Through adding messenger RNA (mRNA) vaccine drug substance production capability to its Songdo facility, Samsung Biologics will be able to provide end-to-end mRNA services.   The contract development manufacturing organization (CDMO) has not disclosed any financial details and a spokeswoman for Samsung Biologics told BioProcess Insider “It would be rather difficult for us to disclose the equipment, skills and financials as the technology’s very new and such information is directly related our competitiveness.”   She continued: “What we can say on our hiring stance is that we continue…

To meet the high demand for lipids, MilliporeSigma has launched its high-purity synthetic cholesterol product nine months early.  “By launching our new SAFC synthetic cholesterol product nine months early, we are able to meet the high demand for lipids that we’re seeing due to the COVID-19 pandemic, as lipids are a key component of mRNA-based vaccines and therapeutics,” Matthias Bucerius, head of Actives & Formulation at MilliporeSigma told us.   The early launch of its cholesterol product has increased its capacity by 50 times.   According to the contract development manufacturing organization (CDMO),…

The European Medicines Agency has recommended the approval of additional manufacturing capacity at Pfizer’s Puurs, Belgium facility for its COVID-19 vaccine. The expansion, of which no financial details have been disclosed, aims to install additional manufacturing and filling lines. According to the EMA, the recommendation given by the Agency’s Committee for Human Medicines (CHMP) will have a significant and direct impact on the supply of Pfizer’s COVID-19 vaccine. The firm’s partnership with BioNTech saw Pfizer become the first company to…

A triumvirate of CDMO expansions will increase production of Moderna’s COVID-19 vaccine: Lonza will repurpose a suite at a Dutch facility to up drug substance, and Aldevron will increase plasmid DNA supply. Meanwhile, Thermo Fisher will provide fill/finish capacity from North Carolina, as will Samsung Biologics from korea. Last month, Moderna announced plans to increase both internal and third-party production of its mRNA COVID-19 vaccine, currently being rolled out under an FDA Emergency Use Authorization (EUA). This included making an…